ACT Capital Management
Latest statistics and disclosures from Act Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are STAA, XOM, DVN, KRYS, ARWR, and represent 49.02% of Act Capital Management's stock portfolio.
- Added to shares of these 10 stocks: AXSM, ADTN, XOM, VRNA, VTLE, FANG, CMBM, TMDX, ROKU, CVX.
- Started 13 new stock positions in SNOW, CHK, CMBM, RUM, SYRS, ADTN, SAVA, TMDX, VRNA, Denbury. AXSM, CLRB, SQ.
- Reduced shares in these 10 stocks: , IDYA, ARCT, LNTH, ARWR, CF, MRVI, AUPH, U, STAA.
- Sold out of its positions in Adtran, Akerna Corp, AMZN, Ampio Pharmaceuticals, Audacy Inc Cl A, AUPH, CF, Cellectar Biosciences, Helius Medical Technolog Class A, IDYA. LNTH, Livent Corp, Lottery, LTRYW, MRVI, Mogo, NTRA, RYTM, Syros Pharmaceuticals, IMTX.
- Act Capital Management was a net buyer of stock by $1.7M.
- Act Capital Management has $73M in assets under management (AUM), dropping by 1.34%.
- Central Index Key (CIK): 0001442273
Tip: Access up to 7 years of quarterly data
Positions held by ACT Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Act Capital Management
Act Capital Management holds 71 positions in its portfolio as reported in the September 2022 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
STAAR Surgical Company (STAA) | 21.7 | $16M | -2% | 223k | 70.55 |
|
Exxon Mobil Corporation (XOM) | 9.8 | $7.1M | +43% | 82k | 87.30 |
|
Devon Energy Corporation (DVN) | 6.8 | $5.0M | 83k | 60.13 |
|
|
Krystal Biotech (KRYS) | 5.6 | $4.1M | 58k | 69.71 |
|
|
Arrowhead Pharmaceuticals (ARWR) | 5.0 | $3.7M | -18% | 111k | 33.05 |
|
Axsome Therapeutics (AXSM) | 4.5 | $3.3M | NEW | 73k | 44.62 |
|
Chevron Corporation (CVX) | 4.5 | $3.2M | +15% | 23k | 143.69 |
|
Adtran Holdings (ADTN) | 4.1 | $2.9M | NEW | 150k | 19.58 |
|
Envveno Medical (NVNO) | 3.5 | $2.5M | 401k | 6.28 |
|
|
Clearside Biomedical (CLSD) | 3.4 | $2.5M | -3% | 2.2M | 1.13 |
|
Laredo Petroleum (VTLE) | 2.9 | $2.1M | +164% | 34k | 62.86 |
|
Arcturus Therapeutics Hldg I (ARCT) | 2.5 | $1.8M | -46% | 120k | 14.82 |
|
Eiger Biopharmaceuticals | 2.4 | $1.8M | -6% | 235k | 7.53 |
|
Verona Pharma Sponsored Ads (VRNA) | 2.0 | $1.5M | NEW | 144k | 10.22 |
|
Energy Transfer Com Ut Ltd Ptn (ET) | 1.9 | $1.4M | 128k | 11.03 |
|
|
Diamondback Energy (FANG) | 1.7 | $1.3M | +162% | 11k | 120.48 |
|
Myovant Sciences | 1.5 | $1.1M | -7% | 60k | 17.97 |
|
Inmune Bio Ord (INMB) | 1.3 | $937k | -5% | 151k | 6.20 |
|
Inhibikase Therapeutics | 1.2 | $853k | 938k | 0.91 |
|
|
Roku Com Cl A (ROKU) | 1.1 | $761k | +141% | 14k | 56.37 |
|
Affimed Therapeutics B V | 0.9 | $636k | 309k | 2.06 |
|
|
Cambium Networks Corp (CMBM) | 0.8 | $582k | NEW | 34k | 16.92 |
|
Transmedics Group (TMDX) | 0.7 | $522k | NEW | 13k | 41.76 |
|
Stratasys SHS (SSYS) | 0.7 | $504k | -30% | 35k | 14.40 |
|
Champions Oncology Com New (CSBR) | 0.6 | $469k | 63k | 7.50 |
|
|
Icad Com New (ICAD) | 0.6 | $431k | 205k | 2.10 |
|
|
Unity Software (U) | 0.5 | $398k | -52% | 13k | 31.84 |
|
Vista Oil &gas Sab De Cv Spon Ads Each Rep 1 Ord Shs Ser A Sponsored Ads (VIST) | 0.5 | $391k | 42k | 9.42 |
|
|
Denbury | 0.5 | $345k | NEW | 4.0k | 86.25 |
|
Zeta Global Holdings Corp Cl A (ZETA) | 0.5 | $340k | -28% | 52k | 6.60 |
|
Block Cl A (SQ) | 0.5 | $330k | NEW | 6.0k | 55.00 |
|
Fubotv (FUBO) | 0.4 | $284k | -27% | 80k | 3.55 |
|
Qualtek Services Class A Com | 0.4 | $278k | -53% | 139k | 2.01 |
|
Oncocyte | 0.3 | $241k | 330k | 0.73 |
|
|
Chesapeake Energy Corp (CHK) | 0.3 | $236k | NEW | 2.5k | 94.40 |
|
Rumble Com Cl A (RUM) | 0.3 | $234k | NEW | 19k | 12.25 |
|
Leap Therapeutics | 0.3 | $233k | 265k | 0.88 |
|
|
Oncternal Therapeutics | 0.3 | $187k | 210k | 0.89 |
|
|
Cardiff Oncology (CRDF) | 0.3 | $186k | 121k | 1.54 |
|
|
Surface Oncology | 0.2 | $177k | 171k | 1.04 |
|
|
Snowflake Cl A (SNOW) | 0.2 | $170k | NEW | 1.0k | 170.00 |
|
Aspira Womens Health | 0.2 | $155k | -35% | 417k | 0.37 |
|
Digitalocean Hldgs (DOCN) | 0.2 | $145k | -60% | 4.0k | 36.25 |
|
Cassava Sciences (SAVA) | 0.2 | $142k | NEW | 3.4k | 41.76 |
|
Marker Therapeutics Ord | 0.2 | $131k | 354k | 0.37 |
|
|
Neoleukin Therapeutics | 0.2 | $127k | 199k | 0.64 |
|
|
Medicenna Therapeutics Corp. (MDNAF) | 0.2 | $124k | 149k | 0.83 |
|
|
Gritstone Oncology Ord (GRTS) | 0.2 | $122k | 48k | 2.57 |
|
|
Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.1 | $97k | 90k | 1.08 |
|
|
Draganfly Com New (DPRO) | 0.1 | $95k | 135k | 0.70 |
|
|
CBDMD 8% Ser A Cum Pfd (YCBD.PA) | 0.1 | $77k | 22k | 3.50 |
|
|
Cellectar Biosciences Com New (CLRB) | 0.1 | $73k | NEW | 22k | 3.36 |
|
Enlivex Therapeutics (ENLV) | 0.1 | $64k | 15k | 4.27 |
|
|
Superior Drilling Products (SDPI) | 0.1 | $54k | 80k | 0.68 |
|
|
Oyster Point Pharma | 0.1 | $48k | 8.5k | 5.65 |
|
|
Tracon Pharmaceuticals Com New | 0.1 | $48k | 29k | 1.68 |
|
|
Cytosorbents Corp Com New (CTSO) | 0.1 | $48k | 35k | 1.37 |
|
|
Yalla Group Ads (YALA) | 0.1 | $44k | 14k | 3.26 |
|
|
Sio Gene Therapies | 0.1 | $41k | 147k | 0.28 |
|
|
Pds Biotechnology Ord (PDSB) | 0.0 | $36k | 12k | 3.00 |
|
|
Sqz Biotech (SQZB) | 0.0 | $36k | 16k | 2.25 |
|
|
Cyteir Therapeutics | 0.0 | $29k | 15k | 1.93 |
|
|
Cbdmd | 0.0 | $28k | 125k | 0.22 |
|
|
Bioline Rx Sponsored Ads (BLRX) | 0.0 | $25k | 28k | 0.91 |
|
|
Instil Bio | 0.0 | $24k | 5.0k | 4.80 |
|
|
Syros Pharmaceuticals (SYRS) | 0.0 | $23k | NEW | 3.5k | 6.57 |
|
Aravive | 0.0 | $15k | 19k | 0.80 |
|
|
Airsculpt Technologies (AIRS) | 0.0 | $10k | 1.5k | 6.67 |
|
|
Transcode Therapeutics | 0.0 | $7.0k | 6.5k | 1.08 |
|
|
Genetron Holdings Ads | 0.0 | $6.0k | 7.5k | 0.80 |
|
|
Atara Biotherapeutics | 0.0 | $3.0k | -90% | 900.00 | 3.33 |
|
Past Filings by Act Capital Management
SEC 13F filings are viewable for Act Capital Management going back to 2021
- Act Capital Management 2022 Q3 filed Nov. 3, 2022
- Act Capital Management 2022 Q2 filed Aug. 12, 2022
- Act Capital Management 2022 Q1 filed May 11, 2022
- Act Capital Management 2021 Q4 filed Feb. 3, 2022
- ACT Capital 2021 Q3 filed Nov. 16, 2021
- ACT Capital Management 2021 Q2 filed Aug. 16, 2021